Huons announced on the 29th that it has decided to expand the free support of transmitters for the continuous glucose monitor (CGM) 'Dexcom G6' for diabetes patients. The transmitter is a device that ...

Dexcom is hoping to win FDA approval to begin selling its G7 continuous glucose monitor in the U.S. later this year. (Shown here with an Apple Watch). · MedTech Dive · Courtesy of Dexcom A warning ...

After the latest in a series of successful quarters (with $171.2 million in revenue, up 31 percent year over year), DexCom is queuing up some big product launches. On yesterday’s Q4 earnings call, CEO ...

Dexcom, Inc., a leader in continuous glucose monitoring (CGM), announced today that the company has received CE Mark for its Dexcom G6 System for people with diabetes ages two years and up. "The ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...

Dexcom has been abuzz this year amid the European approval—and submission for FDA approval in the U.S.—for its next-generation G7 continuous glucose monitoring system, which promises more accurate ...

The Dexcom G7 continuous glucose monitor (CGM) is as accurate or better than other currently marketed CGM devices for measuring glucose in those with diabetes, new data from a pivotal study suggest.